Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (204)

Advertisement

Research Article Free access | 10.1172/JCI113965

A diabetes-susceptible HLA haplotype is best defined by a combination of HLA-DR and -DQ alleles.

M J Sheehy, S J Scharf, J R Rowe, M H Neme de Gimenez, L M Meske, H A Erlich, and B S Nepom

Research Department, American Red Cross Blood Services, Madison, Wisconsin 53705.

Find articles by Sheehy, M. in: JCI | PubMed | Google Scholar

Research Department, American Red Cross Blood Services, Madison, Wisconsin 53705.

Find articles by Scharf, S. in: JCI | PubMed | Google Scholar

Research Department, American Red Cross Blood Services, Madison, Wisconsin 53705.

Find articles by Rowe, J. in: JCI | PubMed | Google Scholar

Research Department, American Red Cross Blood Services, Madison, Wisconsin 53705.

Find articles by Neme de Gimenez, M. in: JCI | PubMed | Google Scholar

Research Department, American Red Cross Blood Services, Madison, Wisconsin 53705.

Find articles by Meske, L. in: JCI | PubMed | Google Scholar

Research Department, American Red Cross Blood Services, Madison, Wisconsin 53705.

Find articles by Erlich, H. in: JCI | PubMed | Google Scholar

Research Department, American Red Cross Blood Services, Madison, Wisconsin 53705.

Find articles by Nepom, B. in: JCI | PubMed | Google Scholar

Published March 1, 1989 - More info

Published in Volume 83, Issue 3 on March 1, 1989
J Clin Invest. 1989;83(3):830–835. https://doi.org/10.1172/JCI113965.
© 1989 The American Society for Clinical Investigation
Published March 1, 1989 - Version history
View PDF
Abstract

HLA-DR4 is associated with insulin-dependent diabetes mellitus (IDDM) in many populations. Many recent studies suggest that the DR4 effect is really due to DQ3.2, an allele of the nearby DQB1 locus. We used T cell clones, MAb, and allele-specific oligonucleotides to test IDDM and control subjects for DR4 subtypes (Dw4, Dw10, Dw13, and Dw14) and for DR4-associated DQB1 alleles (DQ3.1 and DQ3.2). We find that (a) IDDM is approximately equally associated with alleles of the DRB1 locus (Dw4 and Dw10, combined relative risk, RR = 6.4) and the DQB1 locus (DQ3.2, RR = 5.9); and (b) there is significant interaction, in a statistical sense, between these DR and DQ alleles in IDDM. The only IDDM-associated DR4 haplotypes were those carrying the IDDM-associated alleles at both loci (RR = 12.1); haplotypes with Dw4 or 10 but not DQ3.2, or vice versa, had a RR less than 1. Alternative explanations include: (a) that susceptibility requires specific allelic products of both DR and DQ loci; (b) that the combination of certain DR and DQ alleles marks haplotypes with the true susceptibility allele at a third locus; or (c) that Dw4 and 10 mark haplotypes with an allele at another locus that interacts with DQ3.2. As discussed, this third locus is unlikely to be DQA1 (DQ alpha). The data thus are not easily reconciled with an exclusive effect of HLA-DQ. This information increases our ability to predict IDDM by genetic typing: in the population studied, heterozygotes DR3/[DQ3.2, Dw4] or DR3/[DQ3.2, Dw10] had a relative risk of 38.0 and an absolute risk of 1 in 15.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 830
page 830
icon of scanned page 831
page 831
icon of scanned page 832
page 832
icon of scanned page 833
page 833
icon of scanned page 834
page 834
icon of scanned page 835
page 835
Version history
  • Version 1 (March 1, 1989): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (204)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts